Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283590 | 0.92 | PLA2G10 (0.38) | PLA2G10PLA2G5KDM4EALDH1A1POLB | |
| SCHEMBL6283003 | 0.80 | PLA2G10 (0.42) | PLA2G10PLA2G5ALDH1A1KMT2A | |
| SCHEMBL3470165 | 0.70 | PARP1 (0.37) | PLA2G10PLA2G5 | |
| SCHEMBL7278907 | 0.68 | PLA2G10 (0.45) | PLA2G10PLA2G5KDM4EALDH1A1POLB | |
| SCHEMBL8712263 | 0.68 | PLA2G10 (0.37) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL7278550 | 0.67 | PLA2G10 (0.44) | PLA2G10PLA2G5KDM4EALDH1A1POLB | |
| SCHEMBL24726898 | 0.67 | PLA2G10 (0.39) | PLA2G10PLA2G5KDM4EALDH1A1DDB1 | |
| SCHEMBL1637706 | 0.67 | P2RX7 (0.41) | PLA2G10PLA2G5KDM4EDDB1CRBN | |
| SCHEMBL782927 | 0.67 | CHRM2 (0.40) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL4518744 | 0.67 | GLA (0.53) | KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | claimed |
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1313730-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018378-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | CMA1, CTRL, TPSD1 | PLA2G10 4224/4885PLA2G5 3701/4885KDM4E 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.